Avalyn Pharma Appoints Dr. Robert Meyer to Board

What Happened
Avalyn Pharma Inc. announced on September 15, 2026 that its Board appointed Robert Meyer, M.D., as a Class II director with an initial term expiring at the 2028 annual meeting of stockholders. The Board determined Dr. Meyer is independent under Nasdaq listing standards. Dr. Meyer brings extensive regulatory and industry experience from prior roles at the FDA, Merck, Greenleaf Health (later acquired), and academic positions, and has served on multiple public life sciences boards.

Key Details

• Appointment effective: September 15, 2026; term expires at 2028 annual meeting.
• Compensation: Eligible for an annual cash retainer of $40,000 under the Company’s Non-Employee Director Compensation Policy.
• Equity grants: Initial option to purchase 31,182 shares (vests in equal annual installments over 3 years); annual option grant of 15,591 shares on each future annual meeting date (first annual grant prorated). Exercise price = fair market value on grant date under the 2026 Stock Option and Incentive Plan.
• Background: Former FDA senior official (1994–2007), Merck executive (2007–2013), associate professor/director at University of Virginia (2013–2017), and principal at Greenleaf Health (2018–2024); prior public-board experience includes Chimerix, Translate Bio and Correvio.
• No related-party transactions were reported; Dr. Meyer signed the Company’s standard indemnification agreement.

Why It Matters
This appointment adds a director with deep regulatory and drug-development experience, which is relevant for a clinical-stage biotech navigating FDA interactions and development strategy. Investors should note the compensation mix includes cash retainer and stock options, which could lead to modest future share dilution if exercised. The filing contains no other material agreements or related-party transactions tied to this appointment.